To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks

Inclusion Criteria: 1. Age 18-70 years; 2. met the 2010 ACR and EULAR diagnostic criteria for rheumatoid arthritis (RA), and was diagnosed as RA; 3. After more than 3 months of initial treatment or conventional DMARDs treatment, the disease was still in medium-high disease activity, and DAS28-CRP\>3.2; 4. No birth plan during and within 3 months after the end of the study; 5. Voluntarily sign the informed consent form. Exclusion Criteria: 1. Patients who are using or have used glucocorticoids, tofacitib and biological agents in the past 3 months; 2. At the time of screening, patients were in the acute phase of acute infection or chronic infection; 3. Laboratory test results: Hb\<100g/L; White blood cell count \<4.0×10\^9/L; Platelets \<100×10\^9/L; Liver function (transaminase, bilirubin)\> 2 times the upper limit of normal value; Renal function (SCr) \> the upper limit of normal; 4. Active gastrointestinal disease: gastrointestinal bleeding or active gastrointestinal ulcer and acute gastric mucosal injury diagnosed by gastroenteroscopy in the past three months; 5. A history of severe cardiovascular, cerebrovascular, kidney and other important organs, blood and endocrine system lesions, malignant tumors and thrombosis; 6. suffering from serious, progressive and uncontrolled diseases of other important organs and systems; 7. mental disease patients; 8. Other conditions deemed unsuitable for trial participation by the investigator; 9. Pregnancy tests of women of childbearing age were positive.